These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 27474233)
1. Triggering Intracellular Receptors for Vaccine Adjuvantation. Gutjahr A; Tiraby G; Perouzel E; Verrier B; Paul S Trends Immunol; 2016 Sep; 37(9):573-587. PubMed ID: 27474233 [TBL] [Abstract][Full Text] [Related]
2. Novel Adjuvants and Immunomodulators for Veterinary Vaccines. Heegaard PM; Fang Y; Jungersen G Methods Mol Biol; 2016; 1349():63-82. PubMed ID: 26458830 [TBL] [Abstract][Full Text] [Related]
3. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Marciani DJ Drug Discov Today; 2003 Oct; 8(20):934-43. PubMed ID: 14554157 [TBL] [Abstract][Full Text] [Related]
4. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions. Lang R; Schoenen H; Desel C Immunobiology; 2011 Nov; 216(11):1184-91. PubMed ID: 21742403 [TBL] [Abstract][Full Text] [Related]
5. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Leroux-Roels G Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254 [TBL] [Abstract][Full Text] [Related]
6. Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses. Vasou A; Sultanoglu N; Goodbourn S; Randall RE; Kostrikis LG Viruses; 2017 Jul; 9(7):. PubMed ID: 28703784 [TBL] [Abstract][Full Text] [Related]
7. The path forward. De Gregorio E Vaccine; 2015 Jun; 33 Suppl 2():B60-3. PubMed ID: 26022572 [TBL] [Abstract][Full Text] [Related]
8. [The importance of the second generation adjuvanted systems in "new" vaccines]. Beran J Klin Mikrobiol Infekc Lek; 2008 Feb; 14(1):5-12. PubMed ID: 18327735 [TBL] [Abstract][Full Text] [Related]
11. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556 [TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin M as a vaccine adjuvant. Ilag LL Med Hypotheses; 2011 Oct; 77(4):473-8. PubMed ID: 21723670 [TBL] [Abstract][Full Text] [Related]
13. Molecular signatures of vaccine adjuvants. Olafsdottir T; Lindqvist M; Harandi AM Vaccine; 2015 Sep; 33(40):5302-7. PubMed ID: 25989447 [TBL] [Abstract][Full Text] [Related]
14. Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032 [TBL] [Abstract][Full Text] [Related]
15. New adjuvants for human vaccines. Mbow ML; De Gregorio E; Valiante NM; Rappuoli R Curr Opin Immunol; 2010 Jun; 22(3):411-6. PubMed ID: 20466528 [TBL] [Abstract][Full Text] [Related]
16. Combination of adjuvants: the future of vaccine design. Mount A; Koernig S; Silva A; Drane D; Maraskovsky E; Morelli AB Expert Rev Vaccines; 2013 Jul; 12(7):733-46. PubMed ID: 23885819 [TBL] [Abstract][Full Text] [Related]
17. Rationally-designed vaccine adjuvants: separating efficacy from toxicity. Hauguel TM; Hackett CJ Front Biosci; 2008 Jan; 13():2806-13. PubMed ID: 17981755 [TBL] [Abstract][Full Text] [Related]
18. Adjuvants for veterinary vaccines--types and modes of action. Gerdts V Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):456-63. PubMed ID: 26697712 [TBL] [Abstract][Full Text] [Related]
19. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Nicholls EF; Madera L; Hancock RE Ann N Y Acad Sci; 2010 Dec; 1213():46-61. PubMed ID: 20946578 [TBL] [Abstract][Full Text] [Related]